PTCH1 and neoplasm: The aim of the novel phase 2 study on taladegib, currently awaiting recruitment, is to evaluate the efficacy and safety in patients with loss of function of PTCH1 and advanced solid tumours based on occurring adverse events (AEs) and Response Evaluation Criteria in Solid Tumours (RECIST1.1) [151].